Cargando…

A GIP Receptor Agonist Exhibits β-Cell Anti-Apoptotic Actions in Rat Models of Diabetes Resulting in Improved β-Cell Function and Glycemic Control

AIMS: The gastrointestinal hormone GIP promotes pancreatic islet function and exerts pro-survival actions on cultured β-cells. However, GIP also promotes lipogenesis, thus potentially restricting its therapeutic use. The current studies evaluated the effects of a truncated GIP analog, D-Ala(2)-GIP(1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Widenmaier, Scott B., Kim, Su-Jin, Yang, Gary K., De Los Reyes, Thomas, Nian, Cuilan, Asadi, Ali, Seino, Yutaka, Kieffer, Timothy J., Kwok, Yin Nam, McIntosh, Christopher H. S.
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2834736/ https://www.ncbi.nlm.nih.gov/pubmed/20231880 http://dx.doi.org/10.1371/journal.pone.0009590

Ejemplares similares

GIP-Overexpressing Mice Demonstrate Reduced Diet-Induced Obesity and Steatosis, and Improved Glucose Homeostasis
por: Kim, Su-Jin, et al.
Publicado: (2012)

Glucose‐dependent insulinotropic polypeptide signaling in pancreatic β‐cells and adipocytes
por: McIntosh, Christopher HS, et al.
Publicado: (2012)

Ectopic Expression of GIP in Pancreatic β-Cells Maintains Enhanced Insulin Secretion in Mice With Complete Absence of Proglucagon-Derived Peptides
por: Fukami, Ayako, et al.
Publicado: (2013)

Resistin Knockout Mice Exhibit Impaired Adipocyte Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR) Expression
por: Kim, Su-Jin, et al.
Publicado: (2013)

GIP and GLP‐1, the two incretin hormones: Similarities and differences
por: Seino, Yutaka, et al.
Publicado: (2010)

The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction
por: Rizvi, Ali A, et al.
Publicado: (2022)

Species‐specific action of (Pro3)GIP – a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors
por: Sparre‐Ulrich, A H, et al.
Publicado: (2015)

The Incretin Effect in Female Mice With Double Deletion of GLP-1 and GIP Receptors
por: Ahrén, Bo, et al.
Publicado: (2019)

Regulation of GIP and GLP1 Receptor Cell Surface Expression by N-Glycosylation and Receptor Heteromerization
por: Whitaker, Gina M., et al.
Publicado: (2012)

GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells
por: El, K., et al.
Publicado: (2021)

Noninvasive Evaluation of GIP Effects on β-Cell Mass Under High-Fat Diet
por: Kiyobayashi, Sakura, et al.
Publicado: (2022)

Sitagliptin (MK0431) Inhibition of Dipeptidyl Peptidase IV Decreases Nonobese Diabetic Mouse CD4(+) T-Cell Migration Through Incretin-Dependent and -Independent Pathways
por: Kim, Su-Jin, et al.
Publicado: (2010)

Glucose-dependent Insulinotropic Polypeptide (GIP) Resistance and β-cell Dysfunction Contribute to Hyperglycaemia in Acromegaly
por: Shekhawat, Vikram Singh, et al.
Publicado: (2019)

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
por: Willard, Francis S., et al.
Publicado: (2020)

Dipeptidyl Peptidase IV Inhibition With MK0431 Improves Islet Graft Survival in Diabetic NOD Mice Partially via T-Cell Modulation
por: Kim, Su-Jin, et al.
Publicado: (2009)

The Insulin Response to Oral Glucose in GIP and GLP-1 Receptor Knockout Mice: Review of the Literature and Stepwise Glucose Dose Response Studies in Female Mice
por: Ahrén, Bo, et al.
Publicado: (2021)

The insulinogenic effect of whey protein is partially mediated by a direct effect of amino acids and GIP on β-cells
por: Salehi, Albert, et al.
Publicado: (2012)

GLP‐1 receptor agonist attenuates endoplasmic reticulum stress‐mediated β‐cell damage in Akita mice
por: Yamane, Shunsuke, et al.
Publicado: (2011)

Role of a Dual Glucose-Dependent Insulinotropic Peptide (GIP)/Glucagon-like Peptide-1 Receptor Agonist (Twincretin) in Glycemic Control: From Pathophysiology to Treatment
por: Pelle, Maria Chiara, et al.
Publicado: (2021)

GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists
por: Holst, Jens Juul, et al.
Publicado: (2020)

Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
por: Urva, Shweta, et al.
Publicado: (2021)

What combines best with GLP-1 for obesity treatment: GIP receptor agonists or antagonists?
por: Holst, Jens Juul
Publicado: (2021)

Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
por: Urva, Shweta, et al.
Publicado: (2022)

β Cell Dysfunction Versus Insulin Resistance in the Pathogenesis of Type 2 Diabetes in East Asians
por: Yabe, Daisuke, et al.
Publicado: (2015)

Enhanced agonist residence time, internalization rate and signalling of the GIP receptor variant [E354Q] facilitate receptor desensitization and long‐term impairment of the GIP system
por: Gabe, Maria Buur Nordskov, et al.
Publicado: (2019)

GIP: An Inconsequential Incretin or Not?
por: Pratley, Richard E.
Publicado: (2010)

Physiologic and Pharmacologic Modulation of Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Expression in β-Cells by Peroxisome Proliferator–Activated Receptor (PPAR)-γ Signaling: Possible Mechanism for the GIP Resistance in Type 2 Diabetes
por: Gupta, Dhananjay, et al.
Publicado: (2010)

GIP1 and GIP2 Contribute to the Maintenance of Genome Stability at the Nuclear Periphery
por: Singh, Gaurav, et al.
Publicado: (2022)

Marked Cortisol Production by Intracrine ACTH in GIP-Treated Cultured Adrenal Cells in Which the GIP Receptor Was Exogenously Introduced
por: Fujii, Hiroko, et al.
Publicado: (2014)

Endogenous GIP ameliorates impairment of insulin secretion in proglucagon-deficient mice under moderate beta cell damage induced by streptozotocin
por: Iida, Atsushi, et al.
Publicado: (2016)

Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes
por: Thomas, Melissa K, et al.
Publicado: (2020)

GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist–Induced Nausea and Emesis in Preclinical Models
por: Borner, Tito, et al.
Publicado: (2021)

Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
por: Knerr, Patrick J., et al.
Publicado: (2022)

Mechanism of Cancer Growth Suppression of Alpha-Fetoprotein Derived Growth Inhibitory Peptides (GIP): Comparison of GIP-34 versus GIP-8 (AFPep). Updates and Prospects
por: Mizejewski, Gerald J.
Publicado: (2011)

Link Between GIP and Osteopontin in Adipose Tissue and Insulin Resistance
por: Ahlqvist, Emma, et al.
Publicado: (2013)

Pleiotropic Effects of GIP on Islet Function Involve Osteopontin
por: Lyssenko, Valeriya, et al.
Publicado: (2011)

Current status of regeneration of pancreatic β‐cells
por: Minami, Kohtaro, et al.
Publicado: (2013)

Proinflammatory Cytokines Activate the Intrinsic Apoptotic Pathway in β-Cells
por: Grunnet, Lars G., et al.
Publicado: (2009)

Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
por: Gallwitz, Baptist
Publicado: (2022)

Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages
por: Whitley, Heather P., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lub1fptbgfmstfbd87afai3971